Actos Bladder Cancer Lawsuit
European Commission advocates Actos as valid treatment

Despite the concerns associated with the linkage between Actos and bladder cancer, the European Commission advocates that Actos is still a valid treatment for type II diabetes. The decision made by European health officials supports the findings of a study conducted by the European Medicine’s Agency Committee for Medical Products for Human Use (CHMP) which ruled against a recall of Actos mandated by France during the summer of 2011.

France and Germany, the European Union’s two most powerful members, recalled Actos due to the results of a French study conducted by insurance companies which determined that there is an increased risk for bladder cancer with Actos long term use.

As a result of the decision made by the European Commission, stronger warning labels regarding the long term side effects of Actos will be mandated along with more intense patient screenings which will take place in all of Europe except France and Germany.

Actos was first introduced in July of 1999. Prescribed to treat type II diabetes, the drug became popular for its ability to effectively regulate insulin. In September of 2010, Actos became so successful that it brought in revenues for manufacturer Takeda Pharmaceuticals of $4.3 billion.

Although millions of patients have taken Actos, many of them have filed complaints against Takeda Pharmaceuticals claiming that Actos side effects include bladder cancer. Takeda Pharmaceuticals has also been accused of not appropriately researching the product and for failing to issue proper warnings. After performing a thorough review of the product, the U.S. Food and Drug Administration (FDA) issued new warning labels in August 2011.

All federal Actos lawsuits filed against Takeda Pharmaceuticals were transferred to one judge for coordinate pre-trial proceedings as ordered by the U.S. Judicial Panel on Multidistrict Litigation. On December 29th, 2011 the panel of federal judges made the decision to centralize Actos litigation before U.S. District Judge Rebecca F. Doherty in the Western District of Louisiana.


About the Contributor

Related Posts